^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EGFR806-specific CAR T-cell therapy

    i
    Company:
    Cellevolve Bio, Seattle Children's Hospital, Seattle Children’s Therapeutics
    Drug class:
    EGFR-targeted CAR-T immunotherapy
    Related drugs:
    Apply
    EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-01) (NCT03618381)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    06/18/2019
    Primary completion :
    06/01/2025
    Completion :
    06/01/2040
    EGFR
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (NCT03638167)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    10/27/2023
    Initiation :
    03/19/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2040
    EGFR
    |
    EGFR expression • EGFR positive
    |
    EGFR806-specific CAR T-cell therapy